MCP-1 and fetuin A levels in patients with PCOS and/or obesity before and after metformin treatment
The aim of the study was to investigate MCP-1 and fetuin A levels in women with PCOS and/or obesity before and after metformin treatment.
In the study consisted of 59 patients. Anthropometric measurements and biochemical tests, including MCP-1 and fetuin A measurement, were performed. For patients that were diagnosed with insulin resistance and started metformin treatment all the laboratory tests and anthropometric measurements were repeated after 6 months.
MCP-1 and fetuin A levels did not differ between patients with obesity with and without PCOS, between patients with PCOS with and without obesity, insulin resistance, arterial hypertension, dyslipidemia or menstrual disturbances. MCP-1 levels were significantly higher in patients with hyperandrogenemia than in patients without (456.3±141.1pmol/L vs. 372.5±108.5 pmol/L), while fetuin A levels were significantly higher in patients with metabolic syndrome (MetS) than in patients without MetS (278.5±41.1 mcg/ml vs. 240.0±42.0 mcg/ml). There was no significant change in MCP-1 and fetuin A levels after of metformin treatment.
MCP- 1 levels are higher in patients with hyperandrogenemia and fetiun A levels are higher in patients with metabolic syndrome. MCP-1 and fetuin A levels do not change significantly after metformin treatment.
KeywordsAtherosclerosis Cardiovascular risk Metabolic syndrome
Unable to display preview. Download preview PDF.
- Glintborg, D., et al., Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment. Clin Endocrinol (Oxf), 2009. 71(5): p. 652–658CrossRefGoogle Scholar
- Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod, 2004. 19(1): p. 41–47Google Scholar
- Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser, 1995. 854: p. 1–452Google Scholar